Biotech · Private company · Rockville, MD, US
Abvacc, Inc.
Track this companyFree. Adds Abvacc, Inc. to your Dealase workspace and tells you when its record changes.
Clinical trials0None registered
Pipeline programs0None found yet
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
NIH awards10
- Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseFiscal year 2026 · $697.2KNIH RePORTER 5R01AI111205-10 · fetched Nov 12, 2026
- A multimodal approach for immunotherapy of Staphylococcus aureus bacteremiaFiscal year 2026 · $642.1KNIH RePORTER 5R01AI193221-02 · fetched Nov 12, 2026
- Monoclonal Antibody Cocktail for Treatment of Marburg Virus DiseaseFiscal year 2026 · $1MNIH RePORTER 5R44AI179371-03 · fetched Nov 12, 2026
- A multimodal approach for immunotherapy of Staphylococcus aureus bacteremiaFiscal year 2025 · $639KNIH RePORTER 1R01AI193221-01 · fetched Nov 12, 2026
- Monoclonal Antibody Cocktail for Treatment of Marburg Virus DiseaseFiscal year 2025 · $1MNIH RePORTER 4R44AI179371-02 · fetched Nov 12, 2026
- Multivalent Toxoid Vaccine for recurrent Staphylococccus aureus diseaseFiscal year 2025 · $646.1KNIH RePORTER 5R01AI111205-09 · fetched Nov 12, 2026
- Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonistFiscal year 2025 · $297.1KNIH RePORTER 5R43AI181292-02 · fetched Nov 12, 2026
- Prophylactic Immunotherapy for Marburg Virus Disease Outbreak ControlFiscal year 2025 · $914.8KNIH RePORTER 5R44AI177045-03 · fetched Nov 12, 2026
- Development of Therapeutic Products for Marburg VirusFiscal year 2025 · $22KNIH RePORTER 75N93021C00021-P00011-9999-1 · fetched Nov 12, 2026
- Development of a Marburgvirus subunit vaccineadjuvanted with a novel TLR7/TLR8 agonistFiscal year 2024 · $299.5KNIH RePORTER 1R43AI181292-01 · fetched Nov 12, 2026